Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure

• Status: Completed
• Trial end date: 2018-12-30
• Target enrollment: 0
• Participant gender: All

Summary

A number of 100 patients with pulmonary hypertension associated with the left Heart failure scheduled for elective pulmonary arterial denervation (PADN) are randomized 1:1 to either PADN or control group.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing First Hospital, Nanjing Medical University; The First Affiliated Hospital with Nanjing Medical University
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diuretics; Mineralocorticoid Receptor Antagonists

Criteria

Inclusion Criteria:

• Age>18yr

• "Reactive"Pulmonary Hypertension in Left Heart Failure: mPAP≥25 mmHg, PCWP>15 mmHg and pulmonary vascular resistance (PVR) [The PVR =(mPAP-PCWP)/ carbon monoxide]>3.0 woods unit

• Voluntary acceptance of all follow-up assessment of program requirements.

Exclusion Criteria:

• WHO group I, III, IV, V pulmonary artery hypertension

• Severe Renal dysfunction (Ccr<30 ml/min)

• Blood platelet count<100,000/L

• Expected life span<12-month

• In pregnancy

• Systematical inflammation

• Malignant cancer(s)

• Tricuspid valve stenosis, Supra-pulmonary valve stenosis

• Allergic to studied drugs or metal materials